Latest Earnings Results: Q2 '26
Estimated EPS
$0.42
Reported EPS
$0.53
Surprise
+24.51%
Estimated Rev
$205.31M
Reported Rev
$219.06M
Surprise
+6.7%
• Reported GAAP EPS of -$1.01 down -352.50% YoY • Reported revenue of $219.06M up 32.40% YoY • Supernus Pharmaceuticals is raising its full year 2026 financial guidance, now projecting total revenues in the range of $860 million to $890 million, compared to the previous $840 million to $870 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.62 | -- | -- | N/A |
Q2 '26 | $0.42 | $0.53 | 24.51% | BEAT |
Q1 '26 | $0.30 | $0.60 | 102.30% | BEAT |
Q4 '25 | $0.34 | $0.85 | 148.68% | BEAT |
Q3 '25 | $0.59 | $1.01 | 70.41% | BEAT |